Skip to main content
Livermore
Livermore
中文EN

Biovie Inc.

BIVIW
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001580149

In the last 90 days, Biovie Inc. insiders filed 4 open-market purchases and 0 sales; 8 institutions reported holding it in 13F filings for Q2 2026, worth $1.07M in total; no superinvestor holds it.

Other share classesBIVI

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Biovie Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
4 filings
4 insiders, $49.1K in total
Open-market sells
0 filings
Insiders trading
4
Net value
+$49.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Biovie Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Biovie Inc.
NameTitleLast reported holdingLast filingFilings, past year
Palumbo Joseph MChief Medical Officer6,036Aug 28, 20262
Chappell Amy SuzonDirector727Aug 28, 20262
Kim Joanne WendyChief Financial Officer3,441Aug 28, 20262
Do Cuong VPresident & CEO16,117Aug 28, 20262
Rogich SigmundDirector36,926Jan 9, 20261
Lang James PaulDirector68,622Jan 9, 20261
Sherman Michael EdwardDirector–Jan 9, 20261
Farag Kameel D.Director–Jan 9, 20261
Berman Richard JDirector40,643Jan 7, 20250
Hariri Robert JDirector42,254Jan 7, 20250
Gorlin SteveDirector46,358Dec 6, 20230
Reading ChristopherEVP Neuroscience R&D37,148Feb 22, 20230
Markham PenelopeEVP Liver Cirrhosis R&D47,841Feb 22, 20230
Ahlem Clarence N.EVP Neuroscience Product Dev.37,148Feb 22, 20230
Peizer Terren SDirector, 10% Owner19,529,846IndirectJan 18, 20230
Adams Jonathan MEVP Liver Cirrhosis Programs48,630Feb 16, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 28, 2026 (view filing)9:01 PM ETAug 28Same dayPalumbo Joseph MChief Medical OfficerPPurchase+4.84K$2.16+$10.5K+406.0%6.04K after
Aug 28, 2026 (view filing)9:01 PM ETAug 28Same dayChappell Amy SuzonDirectorPPurchase+727$2.16+$1.57KNew position727 after
Aug 28, 2026 (view filing)8:58 PM ETAug 28Same dayKim Joanne WendyChief Financial OfficerPPurchase+2.50K$2.18+$5.45K+265.7%3.44K after
Aug 28, 2026 (view filing)8:57 PM ETAug 271 dayDo Cuong VPresident & CEOPPurchase+15.2K$2.08+$31.6K+1,677.0%16.1K after
Aug 13, 2025 (view filing)Aug 76 daysLateDo Cuong VPresident & CEOPPurchase+5.00K––+100.2%9.99K after
Aug 13, 2025 (view filing)Aug 76 daysLateDo Cuong VPresident & CEOPPurchase+5.00K–––5.05K afterDerivative
Mar 6, 2024 (view filing)Mar 42 daysDo Cuong VPresident & CEOPPurchase+10.0K––+2.3%435.9K after
Mar 6, 2024 (view filing)Mar 42 daysDo Cuong VPresident & CEOPPurchase+5.00K–––5.00K afterDerivative
Dec 6, 2023 (view filing)Dec 15 daysLateGorlin SteveDirectorSSale−75.7K$1.69−$127.9K−62.0%46.4K after
Dec 1, 2023 (view filing)Nov 301 dayDo Cuong VPresident & CEOPPurchase+10.0K$1.78+$17.8K+17.0%68.8K after
Sep 7, 2023 (view filing)Sep 52 daysGorlin SteveDirectorSSale−8.56K$3.05−$26.1K−10.2%75.7K after
Aug 24, 2023 (view filing)Aug 222 daysBerman Richard JDirectorSSale−10.8K$3.50−$37.8K−39.2%16.8K after
Jun 15, 2023 (view filing)May 22-Jun 724 daysLateBerman Richard JDirectorSSale−11.0K$6.12−$67.3K−32.1%23.2K after2 lots
Apr 6, 2023 (view filing)Mar 27-2810 daysLateBerman Richard JDirectorSSale−11.0K$8.52−$93.6K−24.3%34.2K after3 lots
Aug 26, 2022 (view filing)5:10 PM ETJul 3, 20181,515 daysLatePeizer Terren SDirector, 10% OwnerPPurchase+3.31M–––1.71M afterDerivative2 lots
Dec 9, 2021 (view filing)Dec 72 daysKim Joanne WendyCFOPPurchaseClass A common stock, par value $0.0001+2.00K$5.40+$10.8KNew position2.00K after